INVO Bioscience IncNASDAQ:INVONASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.9901/ 1
- Ask / Lots1.0000/ 2
- Open / Previous Close0.0000 / 1.0000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INVO |
|---|---|---|
| 09:34 ET | 9161 | 1.02 |
| 09:36 ET | 2803 | 1.0206 |
| 09:39 ET | 4300 | 1.0201 |
| 09:41 ET | 200 | 1.0696 |
| 09:43 ET | 350 | 1.02 |
| 09:48 ET | 1813 | 1.045 |
| 10:03 ET | 197 | 1.02 |
| 10:06 ET | 800 | 1.02 |
| 10:08 ET | 520 | 1.0201 |
| 10:21 ET | 2302 | 1.02 |
| 10:24 ET | 250 | 1.0467 |
| 10:28 ET | 100 | 1.035 |
| 10:30 ET | 100 | 1.04 |
| 10:32 ET | 361 | 1.02 |
| 10:35 ET | 100 | 1.045 |
| 11:20 ET | 100 | 1.05 |
| 11:24 ET | 1200 | 1.0301 |
| 11:26 ET | 600 | 1.0486 |
| 11:27 ET | 100 | 1.03 |
| 11:29 ET | 500 | 1.049 |
| 11:45 ET | 5000 | 1.0499 |
| 11:51 ET | 171 | 1.0396 |
| 11:54 ET | 1500 | 1.034 |
| 11:56 ET | 382 | 1.04 |
| 12:02 ET | 100 | 1.0406 |
| 12:03 ET | 378 | 1.03 |
| 12:23 ET | 1200 | 1.0301 |
| 12:34 ET | 120 | 1.03 |
| 12:39 ET | 2500 | 1.0315 |
| 12:43 ET | 1034 | 1.0301 |
| 12:50 ET | 805 | 1.0301 |
| 12:54 ET | 4502 | 1.0231 |
| 01:01 ET | 3998 | 1.02 |
| 01:03 ET | 1561 | 1.001 |
| 01:06 ET | 2083 | 1.02 |
| 01:08 ET | 100 | 1.0217 |
| 01:30 ET | 735 | 1.0036 |
| 01:33 ET | 150 | 1.0001 |
| 01:35 ET | 2500 | 1.02 |
| 01:44 ET | 135 | 1 |
| 01:48 ET | 150 | 1.02 |
| 01:51 ET | 600 | 1.0004 |
| 02:09 ET | 160 | 1.0362 |
| 02:15 ET | 300 | 1.02 |
| 02:20 ET | 2290 | 1.01 |
| 02:38 ET | 6870 | 1.0101 |
| 02:44 ET | 948 | 1.005 |
| 02:47 ET | 10645 | 1 |
| 03:02 ET | 3500 | 1.0001 |
| 03:05 ET | 200 | 1.005 |
| 03:23 ET | 5716 | 1.0001 |
| 03:27 ET | 5000 | 1.0099 |
| 03:30 ET | 2500 | 1.005 |
| 03:41 ET | 157 | 1.0099 |
| 03:45 ET | 959 | 1.005 |
| 03:50 ET | 5149 | 1.0099 |
| 03:52 ET | 400 | 1.001 |
| 03:54 ET | 4913 | 0.9901 |
| 03:56 ET | 1300 | 1.0024 |
| 03:57 ET | 292 | 1.005 |
| 03:59 ET | 1034 | 1 |
Apr 16, 2024
INVO Reports Fourth Quarter and Full Year 2023 Financial Results, from 4:59PM ET on Tuesday Apr 16, 2024 by Dow Jones
4:59PM ET on Tuesday Apr 16, 2024 by Dow JonesPress Release: INVO Reports Fourth Quarter and Full Year 2023 Financial Results, from 4:59PM ET on Tuesday Apr 16, 2024 by Dow Jones
4:59PM ET on Tuesday Apr 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
INVO Bioscience Inc | 2.7M | -0.1x | --- |
Tenon Medical Inc | 2.8M | -0.1x | --- |
SINTX Technologies Inc | 2.3M | 0.0x | --- |
Vycor Medical Inc | 2.7M | -6.9x | --- |
Nanovibronix Inc | 2.0M | -0.3x | --- |
Innovative Eyewear Inc | 2.6M | -0.3x | --- |
Company Information
INVO Bioscience, Inc. is a healthcare services fertility company. The Company is focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. The Company’s flagship product is INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. Its treatment solution is the intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. Its technique, designated as IVC, provides patients a more connected and intimate experience at a more affordable cost in comparison to in vitro fertilization (IVF), the other advanced ART treatment. Its commercialization strategy is focused on the opening of INVO Centers offering the INVOcell and IVC procedure and the acquisition of existing IVF clinics. The Company operates three INVO Centers in North America.
Contact Information
- Headquarters
- 5582 Broadcast CtLAKEWOOD RANCH, FL, United States 34240-8471
- Phone
- 978-878-9505
- Fax
- ---
Executives
- Chief Executive Officer, Director
- Steven Shum
- Chief Financial Officer
- Andrea Goren
- Chief Operating Officer, Vice President - Business Development
- Michael Campbell
- Independent Director
- Trent Davis
- Independent Director
- Rebecca Messina
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7M |
|---|---|
Revenue (TTM) | $3.0M |
Shares Outstanding | 2.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.49 |
EPS | $-9.13 |
Book Value | $0.36 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 0.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -232.41% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
